Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
Domains
Life Sciences [q-bio]
Fichier principal
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10.pdf (380)
Télécharger le fichier
Origin | Publisher files allowed on an open archive |
---|
Loading...